Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARYA SCIENCES ACQUISITION CORP.ARYA · Entity 147975 | Director · Chief Financial Officer | October 05, 2018 | October 05, 2018 |
| ARYA Sciences Acquisition Corp VARYE · Entity 137308 | Director · Chief Financial Officer · 10% owner | July 15, 2021 | July 15, 2021 |
| Cerevel Therapeutics Holdings, Inc.ARYB · Entity 15182 | Director · Chief Financial Officer | June 09, 2020 | June 09, 2020 |
| Lyra Therapeutics, Inc.LYRA · Entity 46837 | Director | June 13, 2024 | June 14, 2024 |
| Nautilus Biotechnology, Inc.NAUT · Entity 6679 | Director | June 14, 2024 | June 17, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARYA SCIENCES ACQUISITION CORP.
Report date October 05, 2018 · Filed October 05, 2018
This filing explicitly reported no securities owned.
ARYA Sciences Acquisition Corp V
Report date July 15, 2021 · Filed July 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A ordinary sharesSEC Table I · non-derivative | IndirectBy ARYA Sciences Holdings V | 499,000 |
Reported balance
After 2021-07-15 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-07-15 · Grant · Acquired 499,000 · Balance 499,000 F1: The reported Class A ordinary shares were purchased in a private placement by ARYA Sciences Holdings V (the "Sponsor") for $10.00 per share, as described in the Issuer's registration statement on Form S-1 (File No. 333-257335). F2: The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported Class A ordinary shares were purchased in a private placement by ARYA Sciences Holdings V (the "Sponsor") for $10.00 per share, as described in the Issuer's registration statement on Form S-1 (File No. 333-257335).
F2: The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor.
Cerevel Therapeutics Holdings, Inc.
Report date June 09, 2020 · Filed June 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A ordinary sharesSEC Table I · non-derivative | IndirectBy ARYA Sciences Holdings II | 499,000 |
Reported balance
After 2020-06-09 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-06-09 · Other · Acquired 499,000 · Balance 499,000 F1: The reported Class A ordinary shares are within 499,000 of the Issuer's Private Placement Units, as described under the heading "Description of Securities " in the Issuer's registration statement on Form S-1 (File No. 333- 238488), purchased by the ARYA Sciences Holdings II (the "Sponsor") for $10.00 per Private Placement Unit. F2: The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and the Reporting Person. As such, Mr. Stone and the Reporting Person have voting and investment discretion with respect to the Class A ordinary shares held of record by the Sponsor and may be deemed to have shared beneficial ownership of the Class A ordinary shares held directly by the Sponsor. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported Class A ordinary shares are within 499,000 of the Issuer's Private Placement Units, as described under the heading "Description of Securities " in the Issuer's registration statement on Form S-1 (File No. 333- 238488), purchased by the ARYA Sciences Holdings II (the "Sponsor") for $10.00 per Private Placement Unit.
F2: The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and the Reporting Person. As such, Mr. Stone and the Reporting Person have voting and investment discretion with respect to the Class A ordinary shares held of record by the Sponsor and may be deemed to have shared beneficial ownership of the Class A ordinary shares held directly by the Sponsor.
Lyra Therapeutics, Inc.
Report date June 13, 2024 · Filed June 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.31 · Expires 2034-06-12 | Direct | 30,000 |
Reported balance
After 2024-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-13 · Grant · Acquired 30,000 · Balance 30,000 F1: This option vests and becomes exercisable on the earlier of (i) June 13, 2025 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests and becomes exercisable on the earlier of (i) June 13, 2025 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date.
Nautilus Biotechnology, Inc.
Report date June 14, 2024 · Filed June 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.56 · Expires 2034-06-14 | Direct | 45,000 |
Reported balance
After 2024-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-14 · Grant · Acquired 45,000 · Balance 45,000 F1: Subject to reporting person's continuous status as a "Service Provider" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to reporting person's continuous status as a "Service Provider" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARYA Sciences Acquisition Corp IV
Report date July 31, 2024 · Filed August 01, 2024
Section 16 reporting ended · disclosed 2024-08-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A ordinary sharesSEC Table I · non-derivative | IndirectBy ARYA Sciences Holdings IV | 0 |
Reported balance
After 2024-07-31 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-07-31 · Disposition to issuer · Disposed 499,000 · Balance 0 F1: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the "Business Combination Agreement" and the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the "New Adagio Common Stock"), on a one-for-one basis. F2: (Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period. F4: The shares are held by ARYA Sciences Holdings IV (the "Sponsor"). The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and the Reporting Person. As such, Mr. Stone and the Reporting Person have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor. |
| Class B ordinary sharesSEC Table II · derivative / convertible security | IndirectBy ARYA Sciences Holdings IV | 2,647,500 |
Reported balance
After 2024-07-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-07-31 · Disposition to issuer · Disposed 1,000,000 · Balance 2,647,500 F3: In connection with the execution of the Business Combination Agreement, the Reporting Person entered into that certain Sponsor Letter Agreement, dated as of February 13, 2024, by and among the Reporting Person, the Issuer, HoldCo, Adagio and certain other individuals (the "Sponsor Letter Agreement"). Pursuant to the Sponsor Letter Agreement, the Reporting Person agreed to forfeit 1,000,000 Class B ordinary shares at, and subject to, the closing of the Business Combination for no consideration. F4: The shares are held by ARYA Sciences Holdings IV (the "Sponsor"). The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and the Reporting Person. As such, Mr. Stone and the Reporting Person have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor. |
| Class B ordinary sharesSEC Table II · derivative / convertible security | IndirectBy ARYA Sciences Holdings IV | 0 |
Reported balance
After 2024-07-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-07-31 · Disposition to issuer · Disposed 2,647,500 · Balance 0 F1: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the "Business Combination Agreement" and the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the "New Adagio Common Stock"), on a one-for-one basis. F2: (Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period. F4: The shares are held by ARYA Sciences Holdings IV (the "Sponsor"). The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and the Reporting Person. As such, Mr. Stone and the Reporting Person have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the "Business Combination Agreement" and the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the "New Adagio Common Stock"), on a one-for-one basis.
F2: (Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period.
F3: In connection with the execution of the Business Combination Agreement, the Reporting Person entered into that certain Sponsor Letter Agreement, dated as of February 13, 2024, by and among the Reporting Person, the Issuer, HoldCo, Adagio and certain other individuals (the "Sponsor Letter Agreement"). Pursuant to the Sponsor Letter Agreement, the Reporting Person agreed to forfeit 1,000,000 Class B ordinary shares at, and subject to, the closing of the Business Combination for no consideration.
F4: The shares are held by ARYA Sciences Holdings IV (the "Sponsor"). The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and the Reporting Person. As such, Mr. Stone and the Reporting Person have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor.
Adagio Medical Holdings, Inc.
Report date September 27, 2024 · Filed October 01, 2024
Jointly reported with ARYA Sciences Holdings IV, Stone Adam Leo
Section 16 reporting ended · disclosed 2024-10-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-09-27 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-09-27 · Other · Disposed 3,501,600 · Balance 0 F1: On September 27, 2024, ARYA Sciences Holdings IV (the "Sponsor") effectuated a pro rata distribution for no consideration to its shareholders of its shares of common stock, par value $0.0001 per share (the "Common Stock"), of Adagio Medical Holdings, Inc. (f/k/a/ Aja HoldCo, Inc.) (the "Issuer"), including 1,147,500 shares of Common Stock that are subject to share price trigger vesting (the "Earn-Out Shares"). Such Earn-Out Shares (i) will vest if, prior to the tenth anniversary (the "Earn-Out Period") of the closing (the "Closing") of the business combination by and among ARYA Sciences Acquisition Corp IV, the Sponsor and the Issuer, the post-Closing share price of Common Stock equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period, or (ii) will automatically be forfeited and cancelled if the foregoing vesting condition is not fulfilled within the Earn-Out Period. F2: The reported securities were directly held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman had voting and investment discretion with respect to any shares of Common Stock that were held of record by the Sponsor and may be deemed to have shared beneficial ownership of any shares of Common Stock that were held directly by the Sponsor. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 27, 2024, ARYA Sciences Holdings IV (the "Sponsor") effectuated a pro rata distribution for no consideration to its shareholders of its shares of common stock, par value $0.0001 per share (the "Common Stock"), of Adagio Medical Holdings, Inc. (f/k/a/ Aja HoldCo, Inc.) (the "Issuer"), including 1,147,500 shares of Common Stock that are subject to share price trigger vesting (the "Earn-Out Shares"). Such Earn-Out Shares (i) will vest if, prior to the tenth anniversary (the "Earn-Out Period") of the closing (the "Closing") of the business combination by and among ARYA Sciences Acquisition Corp IV, the Sponsor and the Issuer, the post-Closing share price of Common Stock equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period, or (ii) will automatically be forfeited and cancelled if the foregoing vesting condition is not fulfilled within the Earn-Out Period.
F2: The reported securities were directly held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman had voting and investment discretion with respect to any shares of Common Stock that were held of record by the Sponsor and may be deemed to have shared beneficial ownership of any shares of Common Stock that were held directly by the Sponsor.
Freenome, Inc.
Report date July 20, 2026 · Filed July 22, 2026
Section 16 reporting ended · disclosed 2026-07-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Perceptive Capital Solutions Holdings | 2,352,500 |
Reported balance
After 2026-07-20 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-07-20 · Conversion · Acquired 2,066,250 · Balance 2,352,500 F1: Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. ("Old Freenome"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the "BCA"), on July 20, 2026 (the "Closing Date"), the Issuer consummated its business combination with Old Freenome (the "Business Combination"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis. F2: The securities reported herein are held by Perceptive Capital Solutions Holdings (the "Sponsor"). The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor. |
| Class B Ordinary SharesSEC Table II · derivative / convertible security | IndirectBy Perceptive Capital Solutions Holdings | 0 |
Reported balance
After 2026-07-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-20 · Conversion · Disposed 2,066,250 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. ("Old Freenome"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the "BCA"), on July 20, 2026 (the "Closing Date"), the Issuer consummated its business combination with Old Freenome (the "Business Combination"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis. F2: The securities reported herein are held by Perceptive Capital Solutions Holdings (the "Sponsor"). The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. ("Old Freenome"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the "BCA"), on July 20, 2026 (the "Closing Date"), the Issuer consummated its business combination with Old Freenome (the "Business Combination"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis.
F2: The securities reported herein are held by Perceptive Capital Solutions Holdings (the "Sponsor"). The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 20, 2026 Filed Jul 22, 2026 23:18 UTC | Freenome, Inc. FRNM · Entity 4644 | ConversionClass B Ordinary Shares · Derivative | 2,066,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001746738-26-000003 · form4-07222026_110718.xml · derivative · entry 2 ALTMAN MICHAEL SETH · CIK 0001746738 · Former Dir, Ofc, 10% Ownr 10b5-1 filing: No plan indicated Ownership: Indirect · By Perceptive Capital Solutions Holdings Disclosed balance after: 0 Underlying: Common Stock · 2,066,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. ("Old Freenome"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the "BCA"), on July 20, 2026 (the "Closing Date"), the Issuer consummated its business combination with Old Freenome (the "Business Combination"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis. F1 · price: Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. ("Old Freenome"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the "BCA"), on July 20, 2026 (the "Closing Date"), the Issuer consummated its business combination with Old Freenome (the "Business Combination"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis. F1 · derivative.exercise_date: Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. ("Old Freenome"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the "BCA"), on July 20, 2026 (the "Closing Date"), the Issuer consummated its business combination with Old Freenome (the "Business Combination"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis. F1 · derivative.expiration_date: Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. ("Old Freenome"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the "BCA"), on July 20, 2026 (the "Closing Date"), the Issuer consummated its business combination with Old Freenome (the "Business Combination"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis. F2 · ownership.nature: The securities reported herein are held by Perceptive Capital Solutions Holdings (the "Sponsor"). The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor. Read SEC document |
| July 20, 2026 Filed Jul 22, 2026 23:18 UTC | Freenome, Inc. FRNM · Entity 4644 | ConversionCommon Stock | 2,066,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001746738-26-000003 · form4-07222026_110718.xml · nonDerivative · entry 1 ALTMAN MICHAEL SETH · CIK 0001746738 · Former Dir, Ofc, 10% Ownr 10b5-1 filing: No plan indicated Ownership: Indirect · By Perceptive Capital Solutions Holdings Disclosed balance after: 2,352,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. ("Old Freenome"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the "BCA"), on July 20, 2026 (the "Closing Date"), the Issuer consummated its business combination with Old Freenome (the "Business Combination"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis. F2 · ownership.nature: The securities reported herein are held by Perceptive Capital Solutions Holdings (the "Sponsor"). The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 20:35 UTC | Adagio Medical Holdings, Inc. ADGM · Entity 7926 | OtherCommon Stock | 3,501,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-042486 · form4.xml · nonDerivative · entry 1 ARYA Sciences Holdings IV · CIK 0001838903 · 10% owner Stone Adam Leo · CIK 0001727440 · 10% owner ALTMAN MICHAEL SETH · CIK 0001746738 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On September 27, 2024, ARYA Sciences Holdings IV (the "Sponsor") effectuated a pro rata distribution for no consideration to its shareholders of its shares of common stock, par value $0.0001 per share (the "Common Stock"), of Adagio Medical Holdings, Inc. (f/k/a/ Aja HoldCo, Inc.) (the "Issuer"), including 1,147,500 shares of Common Stock that are subject to share price trigger vesting (the "Earn-Out Shares"). Such Earn-Out Shares (i) will vest if, prior to the tenth anniversary (the "Earn-Out Period") of the closing (the "Closing") of the business combination by and among ARYA Sciences Acquisition Corp IV, the Sponsor and the Issuer, the post-Closing share price of Common Stock equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period, or (ii) will automatically be forfeited and cancelled if the foregoing vesting condition is not fulfilled within the Earn-Out Period. F1 · price: On September 27, 2024, ARYA Sciences Holdings IV (the "Sponsor") effectuated a pro rata distribution for no consideration to its shareholders of its shares of common stock, par value $0.0001 per share (the "Common Stock"), of Adagio Medical Holdings, Inc. (f/k/a/ Aja HoldCo, Inc.) (the "Issuer"), including 1,147,500 shares of Common Stock that are subject to share price trigger vesting (the "Earn-Out Shares"). Such Earn-Out Shares (i) will vest if, prior to the tenth anniversary (the "Earn-Out Period") of the closing (the "Closing") of the business combination by and among ARYA Sciences Acquisition Corp IV, the Sponsor and the Issuer, the post-Closing share price of Common Stock equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period, or (ii) will automatically be forfeited and cancelled if the foregoing vesting condition is not fulfilled within the Earn-Out Period. F2 · ownership.direct: The reported securities were directly held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman had voting and investment discretion with respect to any shares of Common Stock that were held of record by the Sponsor and may be deemed to have shared beneficial ownership of any shares of Common Stock that were held directly by the Sponsor. Read SEC document |
| July 31, 2024 Filed Aug 1, 2024 01:40 UTC | ARYA Sciences Acquisition Corp IV ARYD · Entity 88618 | Disposition to issuerClass B ordinary shares · Derivative | 2,647,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-035164 · form4.xml · derivative · entry 3 ALTMAN MICHAEL SETH · CIK 0001746738 · Director · Chief Financial Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By ARYA Sciences Holdings IV Disclosed balance after: 0 Underlying: Class A ordinary shares · 2,647,500 shares Expires not disclosed F1 · derivative.exercise_price: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the "Business Combination Agreement" and the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the "New Adagio Common Stock"), on a one-for-one basis. F2 · derivative.exercise_price: (Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period. F1 · kind: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the "Business Combination Agreement" and the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the "New Adagio Common Stock"), on a one-for-one basis. F2 · kind: (Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period. F1 · price: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the "Business Combination Agreement" and the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the "New Adagio Common Stock"), on a one-for-one basis. F2 · price: (Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period. F1 · derivative.exercise_date: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the "Business Combination Agreement" and the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the "New Adagio Common Stock"), on a one-for-one basis. F2 · derivative.exercise_date: (Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period. F1 · derivative.expiration_date: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the "Business Combination Agreement" and the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the "New Adagio Common Stock"), on a one-for-one basis. F2 · derivative.expiration_date: (Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period. F4 · ownership.nature: The shares are held by ARYA Sciences Holdings IV (the "Sponsor"). The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and the Reporting Person. As such, Mr. Stone and the Reporting Person have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor. Read SEC document |
| July 31, 2024 Filed Aug 1, 2024 01:40 UTC | ARYA Sciences Acquisition Corp IV ARYD · Entity 88618 | Disposition to issuerClass B ordinary shares · Derivative | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-035164 · form4.xml · derivative · entry 2 ALTMAN MICHAEL SETH · CIK 0001746738 · Director · Chief Financial Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By ARYA Sciences Holdings IV Disclosed balance after: 2,647,500 Underlying: Class A ordinary shares · 1,000,000 shares Expires not disclosed F3 · derivative.exercise_price: In connection with the execution of the Business Combination Agreement, the Reporting Person entered into that certain Sponsor Letter Agreement, dated as of February 13, 2024, by and among the Reporting Person, the Issuer, HoldCo, Adagio and certain other individuals (the "Sponsor Letter Agreement"). Pursuant to the Sponsor Letter Agreement, the Reporting Person agreed to forfeit 1,000,000 Class B ordinary shares at, and subject to, the closing of the Business Combination for no consideration. F3 · kind: In connection with the execution of the Business Combination Agreement, the Reporting Person entered into that certain Sponsor Letter Agreement, dated as of February 13, 2024, by and among the Reporting Person, the Issuer, HoldCo, Adagio and certain other individuals (the "Sponsor Letter Agreement"). Pursuant to the Sponsor Letter Agreement, the Reporting Person agreed to forfeit 1,000,000 Class B ordinary shares at, and subject to, the closing of the Business Combination for no consideration. F3 · price: In connection with the execution of the Business Combination Agreement, the Reporting Person entered into that certain Sponsor Letter Agreement, dated as of February 13, 2024, by and among the Reporting Person, the Issuer, HoldCo, Adagio and certain other individuals (the "Sponsor Letter Agreement"). Pursuant to the Sponsor Letter Agreement, the Reporting Person agreed to forfeit 1,000,000 Class B ordinary shares at, and subject to, the closing of the Business Combination for no consideration. F3 · derivative.exercise_date: In connection with the execution of the Business Combination Agreement, the Reporting Person entered into that certain Sponsor Letter Agreement, dated as of February 13, 2024, by and among the Reporting Person, the Issuer, HoldCo, Adagio and certain other individuals (the "Sponsor Letter Agreement"). Pursuant to the Sponsor Letter Agreement, the Reporting Person agreed to forfeit 1,000,000 Class B ordinary shares at, and subject to, the closing of the Business Combination for no consideration. F3 · derivative.expiration_date: In connection with the execution of the Business Combination Agreement, the Reporting Person entered into that certain Sponsor Letter Agreement, dated as of February 13, 2024, by and among the Reporting Person, the Issuer, HoldCo, Adagio and certain other individuals (the "Sponsor Letter Agreement"). Pursuant to the Sponsor Letter Agreement, the Reporting Person agreed to forfeit 1,000,000 Class B ordinary shares at, and subject to, the closing of the Business Combination for no consideration. F4 · ownership.nature: The shares are held by ARYA Sciences Holdings IV (the "Sponsor"). The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and the Reporting Person. As such, Mr. Stone and the Reporting Person have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor. Read SEC document |
| July 31, 2024 Filed Aug 1, 2024 01:40 UTC | ARYA Sciences Acquisition Corp IV ARYD · Entity 88618 | Disposition to issuerClass A ordinary shares | 499,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-035164 · form4.xml · nonDerivative · entry 1 ALTMAN MICHAEL SETH · CIK 0001746738 · Director · Chief Financial Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By ARYA Sciences Holdings IV Disclosed balance after: 0 F1 · kind: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the "Business Combination Agreement" and the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the "New Adagio Common Stock"), on a one-for-one basis. F2 · kind: (Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period. F1 · price: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the "Business Combination Agreement" and the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the "New Adagio Common Stock"), on a one-for-one basis. F2 · price: (Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period. F4 · ownership.nature: The shares are held by ARYA Sciences Holdings IV (the "Sponsor"). The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and the Reporting Person. As such, Mr. Stone and the Reporting Person have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 22:03 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $2.56 | $0.00 |
DisclosureSEC source: 0001062993-24-012727 · form4.xml · derivative · entry 1 ALTMAN MICHAEL SETH · CIK 0001746738 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2034-06-14 F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date. Read SEC document |
| June 13, 2024 Filed Jun 13, 2024 20:37 UTC | Freenome, Inc. PCSC · Entity 4644 | GrantClass A ordinary shares | 286,250 | $10.00 | $2,862,500.00 |
DisclosureSEC source: 0001140361-24-030023 · form4.xml · nonDerivative · entry 1 ALTMAN MICHAEL SETH · CIK 0001746738 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Perceptive Capital Solutions Holdings Disclosed balance after: 286,250 F1 · kind: The reported Class A ordinary shares were purchased in a private placement by Perceptive Capital Solutions Holdings (the "Sponsor") for $10.00 per share, as described in the Issuer's registration statement on Form S-1 (File No. 333-279598). F2 · ownership.nature: The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 20:10 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 30,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0000950170-24-073651 · ownership.xml · derivative · entry 1 ALTMAN MICHAEL SETH · CIK 0001746738 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: This option vests and becomes exercisable on the earlier of (i) June 13, 2025 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| June 30, 2023 Filed Jul 6, 2023 01:49 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0000950170-23-031867 · ownership.xml · derivative · entry 1 ALTMAN MICHAEL SETH · CIK 0001746738 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-06-29 F1 · derivative.exercise_date: This option vests and becomes exercisable on June 30, 2024, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| June 15, 2023 Filed Jun 21, 2023 00:52 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0000899243-23-016073 · doc4.xml · derivative · entry 1 ALTMAN MICHAEL SETH · CIK 0001746738 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2033-06-15 F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 20:06 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 7,250 | $0.00 Strike: $5.09 | $0.00 |
DisclosureSEC source: 0000899243-22-023342 · doc4.xml · derivative · entry 1 ALTMAN MICHAEL SETH · CIK 0001746738 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,250 Underlying: Common Stock · 7,250 shares Expires 2032-06-15 F1 · derivative.exercise_date: This option vests and becomes exercisable on the earlier of (i) June 16, 2023 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 21:43 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 86,467 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001062993-22-015188 · form4.xml · derivative · entry 1 ALTMAN MICHAEL SETH · CIK 0001746738 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,467 Underlying: Common Stock · 86,467 shares Expires 2032-06-15 F1 · derivative.exercise_date: Subject to the reporting person's continuous status as a "Service Provider" (as defined in the Issuer's 2021 Equity Incentive Plan) through each vesting date, the shares subject to the Option shall vest on a monthly basis for twelve consecutive months, on the same day of the month as the Grant Date. The Grant Date was June 15, 2022. Read SEC document |
| July 15, 2021 Filed Jul 15, 2021 17:53 UTC | ARYA Sciences Acquisition Corp V ARYE · Entity 137308 | GrantClass A ordinary shares | 499,000 | $10.00 | $4,990,000.00 |
DisclosureSEC source: 0001140361-21-024476 · form4.xml · nonDerivative · entry 1 ALTMAN MICHAEL SETH · CIK 0001746738 · Director · Chief Financial Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By ARYA Sciences Holdings V Disclosed balance after: 499,000 F1 · kind: The reported Class A ordinary shares were purchased in a private placement by ARYA Sciences Holdings V (the "Sponsor") for $10.00 per share, as described in the Issuer's registration statement on Form S-1 (File No. 333-257335). F2 · ownership.nature: The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 21:32 UTC | Nautilus Biotechnology, Inc. [NAUT] · Entity 6679 | GrantStock Option (Right to buy) · Derivative | 44,435 | $0.00 Strike: $11.16 | $0.00 |
DisclosureSEC source: 0001140361-21-020674 · form4.xml · derivative · entry 5 ALTMAN MICHAEL SETH · CIK 0001746738 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,435 Underlying: Common Stock · 44,435 shares Expires 2031-06-09 F4 · security: In connection with the appointment of the Reporting Person to the board of directors of Nautilus (the "Board"), the Board granted on June 9, 2021 the Reporting Person an Initial Award (as defined in the Company's Outside Director Compensation Policy and in accordance with Nautilus' 2021 Equity Incentive Plan (the "Plan"). Subject to the Reporting Person's continuous status as a "Service Provider" (as defined in the the Plan), the Initial Award is scheduled to vest as to one thirty-sixth (1/36th) of the shares of common stock subject to the Initial Award on a monthly basis following the Initial Award's grant date on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month). The grant date is June 9, 2021. F4 · kind: In connection with the appointment of the Reporting Person to the board of directors of Nautilus (the "Board"), the Board granted on June 9, 2021 the Reporting Person an Initial Award (as defined in the Company's Outside Director Compensation Policy and in accordance with Nautilus' 2021 Equity Incentive Plan (the "Plan"). Subject to the Reporting Person's continuous status as a "Service Provider" (as defined in the the Plan), the Initial Award is scheduled to vest as to one thirty-sixth (1/36th) of the shares of common stock subject to the Initial Award on a monthly basis following the Initial Award's grant date on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month). The grant date is June 9, 2021. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 21:32 UTC | Nautilus Biotechnology, Inc. [NAUT] · Entity 6679 | ConversionClass B ordinary shares · Derivative | 3,647,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-020674 · form4.xml · derivative · entry 4 ALTMAN MICHAEL SETH · CIK 0001746738 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · ARYA Sciences Holdings III Disclosed balance after: 0 Underlying: Class A ordinary shares · 3,647,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the Business Combination Agreement, dated February 7, 2021, by and among ARYA Sciences Acquisition Corp III ("ARYA"), Mako Merger Sub, Inc. and Nautilus Biotechnology, Inc. (the transactions contemplated thereby, the "Business Combination"), ARYA domesticated as a Delaware corporation (the "Domestication") and changed its name to "Nautilus Biotechnology, Inc." ("Nautilus"). In connection with the Domestication, ARYA Sciences Holdings III's (the "Sponsor") Class B ordinary shares, par value $0.0001 per share, of ARYA, which were previously convertible into Class A ordinary shares of ARYA (as described in ARYA's registration statement on Form S-1 (File No. 333-239986) under the heading "Description of Securities--Founder Shares"), were automatically converted into shares of common stock of Nautilus, par value $0.0001 per share, on a one-for-one basis. F1 · kind: In connection with the Business Combination Agreement, dated February 7, 2021, by and among ARYA Sciences Acquisition Corp III ("ARYA"), Mako Merger Sub, Inc. and Nautilus Biotechnology, Inc. (the transactions contemplated thereby, the "Business Combination"), ARYA domesticated as a Delaware corporation (the "Domestication") and changed its name to "Nautilus Biotechnology, Inc." ("Nautilus"). In connection with the Domestication, ARYA Sciences Holdings III's (the "Sponsor") Class B ordinary shares, par value $0.0001 per share, of ARYA, which were previously convertible into Class A ordinary shares of ARYA (as described in ARYA's registration statement on Form S-1 (File No. 333-239986) under the heading "Description of Securities--Founder Shares"), were automatically converted into shares of common stock of Nautilus, par value $0.0001 per share, on a one-for-one basis. F1 · price: In connection with the Business Combination Agreement, dated February 7, 2021, by and among ARYA Sciences Acquisition Corp III ("ARYA"), Mako Merger Sub, Inc. and Nautilus Biotechnology, Inc. (the transactions contemplated thereby, the "Business Combination"), ARYA domesticated as a Delaware corporation (the "Domestication") and changed its name to "Nautilus Biotechnology, Inc." ("Nautilus"). In connection with the Domestication, ARYA Sciences Holdings III's (the "Sponsor") Class B ordinary shares, par value $0.0001 per share, of ARYA, which were previously convertible into Class A ordinary shares of ARYA (as described in ARYA's registration statement on Form S-1 (File No. 333-239986) under the heading "Description of Securities--Founder Shares"), were automatically converted into shares of common stock of Nautilus, par value $0.0001 per share, on a one-for-one basis. F1 · derivative.exercise_date: In connection with the Business Combination Agreement, dated February 7, 2021, by and among ARYA Sciences Acquisition Corp III ("ARYA"), Mako Merger Sub, Inc. and Nautilus Biotechnology, Inc. (the transactions contemplated thereby, the "Business Combination"), ARYA domesticated as a Delaware corporation (the "Domestication") and changed its name to "Nautilus Biotechnology, Inc." ("Nautilus"). In connection with the Domestication, ARYA Sciences Holdings III's (the "Sponsor") Class B ordinary shares, par value $0.0001 per share, of ARYA, which were previously convertible into Class A ordinary shares of ARYA (as described in ARYA's registration statement on Form S-1 (File No. 333-239986) under the heading "Description of Securities--Founder Shares"), were automatically converted into shares of common stock of Nautilus, par value $0.0001 per share, on a one-for-one basis. F1 · derivative.expiration_date: In connection with the Business Combination Agreement, dated February 7, 2021, by and among ARYA Sciences Acquisition Corp III ("ARYA"), Mako Merger Sub, Inc. and Nautilus Biotechnology, Inc. (the transactions contemplated thereby, the "Business Combination"), ARYA domesticated as a Delaware corporation (the "Domestication") and changed its name to "Nautilus Biotechnology, Inc." ("Nautilus"). In connection with the Domestication, ARYA Sciences Holdings III's (the "Sponsor") Class B ordinary shares, par value $0.0001 per share, of ARYA, which were previously convertible into Class A ordinary shares of ARYA (as described in ARYA's registration statement on Form S-1 (File No. 333-239986) under the heading "Description of Securities--Founder Shares"), were automatically converted into shares of common stock of Nautilus, par value $0.0001 per share, on a one-for-one basis. F2 · ownership.nature: The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman (the "Reporting Person"). As such, Mr. Stone and the Reporting Person have voting and investment discretion with respect to securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 21:32 UTC | Nautilus Biotechnology, Inc. [NAUT] · Entity 6679 | ConversionCommon Stock | 499,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-020674 · form4.xml · nonDerivative · entry 3 ALTMAN MICHAEL SETH · CIK 0001746738 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · ARYA Sciences Holdings III Disclosed balance after: 499,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: In connection with the Business Combination, the Sponsor's private placement shares, par value $0.0001 per share, of ARYA automatically converted into shares of common stock of Nautilus, par value $0.0001 per share, on a one-for-one basis. F3 · price: In connection with the Business Combination, the Sponsor's private placement shares, par value $0.0001 per share, of ARYA automatically converted into shares of common stock of Nautilus, par value $0.0001 per share, on a one-for-one basis. F2 · ownership.nature: The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman (the "Reporting Person"). As such, Mr. Stone and the Reporting Person have voting and investment discretion with respect to securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 21:32 UTC | Nautilus Biotechnology, Inc. [NAUT] · Entity 6679 | ConversionClass A ordinary shares | 499,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-020674 · form4.xml · nonDerivative · entry 2 ALTMAN MICHAEL SETH · CIK 0001746738 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · ARYA Sciences Holdings III Disclosed balance after: 0 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: In connection with the Business Combination, the Sponsor's private placement shares, par value $0.0001 per share, of ARYA automatically converted into shares of common stock of Nautilus, par value $0.0001 per share, on a one-for-one basis. F3 · price: In connection with the Business Combination, the Sponsor's private placement shares, par value $0.0001 per share, of ARYA automatically converted into shares of common stock of Nautilus, par value $0.0001 per share, on a one-for-one basis. F2 · ownership.nature: The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman (the "Reporting Person"). As such, Mr. Stone and the Reporting Person have voting and investment discretion with respect to securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 21:32 UTC | Nautilus Biotechnology, Inc. [NAUT] · Entity 6679 | ConversionCommon Stock | 3,647,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-020674 · form4.xml · nonDerivative · entry 1 ALTMAN MICHAEL SETH · CIK 0001746738 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · ARYA Sciences Holdings III Disclosed balance after: 3,647,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: In connection with the Business Combination Agreement, dated February 7, 2021, by and among ARYA Sciences Acquisition Corp III ("ARYA"), Mako Merger Sub, Inc. and Nautilus Biotechnology, Inc. (the transactions contemplated thereby, the "Business Combination"), ARYA domesticated as a Delaware corporation (the "Domestication") and changed its name to "Nautilus Biotechnology, Inc." ("Nautilus"). In connection with the Domestication, ARYA Sciences Holdings III's (the "Sponsor") Class B ordinary shares, par value $0.0001 per share, of ARYA, which were previously convertible into Class A ordinary shares of ARYA (as described in ARYA's registration statement on Form S-1 (File No. 333-239986) under the heading "Description of Securities--Founder Shares"), were automatically converted into shares of common stock of Nautilus, par value $0.0001 per share, on a one-for-one basis. F1 · price: In connection with the Business Combination Agreement, dated February 7, 2021, by and among ARYA Sciences Acquisition Corp III ("ARYA"), Mako Merger Sub, Inc. and Nautilus Biotechnology, Inc. (the transactions contemplated thereby, the "Business Combination"), ARYA domesticated as a Delaware corporation (the "Domestication") and changed its name to "Nautilus Biotechnology, Inc." ("Nautilus"). In connection with the Domestication, ARYA Sciences Holdings III's (the "Sponsor") Class B ordinary shares, par value $0.0001 per share, of ARYA, which were previously convertible into Class A ordinary shares of ARYA (as described in ARYA's registration statement on Form S-1 (File No. 333-239986) under the heading "Description of Securities--Founder Shares"), were automatically converted into shares of common stock of Nautilus, par value $0.0001 per share, on a one-for-one basis. F2 · ownership.nature: The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman (the "Reporting Person"). As such, Mr. Stone and the Reporting Person have voting and investment discretion with respect to securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 26, 2021 Filed May 28, 2021 22:28 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 7,250 | $0.00 Strike: $7.24 | $0.00 |
DisclosureSEC source: 0000899243-21-021191 · doc4.xml · derivative · entry 1 ALTMAN MICHAEL SETH · CIK 0001746738 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,250 Underlying: Common Stock · 7,250 shares Expires 2031-05-25 F1 · derivative.exercise_date: This option vests and becomes exercisable on the earlier of (i) May 26, 2022 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| March 02, 2021 Filed Mar 2, 2021 21:30 UTC | ARYA Sciences Acquisition Corp IV ARYD · Entity 88618 | GrantClass A ordinary shares | 499,000 | $10.00 | $4,990,000.00 |
DisclosureSEC source: 0001140361-21-006908 · form4.xml · nonDerivative · entry 1 ALTMAN MICHAEL SETH · CIK 0001746738 · Director · Chief Financial Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By ARYA Sciences Holdings IV Disclosed balance after: 499,000 F1 · kind: The reported Class A ordinary shares were purchased in a private placement by ARYA Sciences Holdings IV (the "Sponsor") for $10.00 per share, as described in the Issuer's registration statement on Form S-1 (File No. 333- 252960). F2 · ownership.nature: The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor. Read SEC document |
| August 11, 2020 Filed Aug 12, 2020 00:38 UTC | Nautilus Biotechnology, Inc. ARYA · Entity 6679 | OtherClass A ordinary shares | 499,000 | $10.00 | $4,990,000.00 |
DisclosureSEC source: 0001140361-20-018160 · form4.xml · nonDerivative · entry 1 ALTMAN MICHAEL SETH · CIK 0001746738 · Director · Chief Financial Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By ARYA Sciences Holdings III Disclosed balance after: 499,000 F1 · kind: The reported Class A ordinary shares were purchased as Private Placement Shares by ARYA Sciences Holdings III (the "Sponsor") for $10.00 per share, as described under the heading "Description of Securities " in the Issuer's registration statement on Form S-1 (File No. 333- 239986). F2 · ownership.nature: The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and the Reporting Person. As such, Mr. Stone and the Reporting Person have voting and investment discretion with respect to the Class A ordinary shares held of record by the Sponsor and may be deemed to have shared beneficial ownership of the Class A ordinary shares held directly by the Sponsor. Read SEC document |
| June 09, 2020 Filed Jun 9, 2020 20:23 UTC | Cerevel Therapeutics Holdings, Inc. ARYB · Entity 15182 | OtherClass A ordinary shares | 499,000 | $10.00 | $4,990,000.00 |
DisclosureSEC source: 0001140361-20-013458 · form4.xml · nonDerivative · entry 1 ALTMAN MICHAEL SETH · CIK 0001746738 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By ARYA Sciences Holdings II Disclosed balance after: 499,000 F1 · kind: The reported Class A ordinary shares are within 499,000 of the Issuer's Private Placement Units, as described under the heading "Description of Securities " in the Issuer's registration statement on Form S-1 (File No. 333- 238488), purchased by the ARYA Sciences Holdings II (the "Sponsor") for $10.00 per Private Placement Unit. F2 · ownership.nature: The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and the Reporting Person. As such, Mr. Stone and the Reporting Person have voting and investment discretion with respect to the Class A ordinary shares held of record by the Sponsor and may be deemed to have shared beneficial ownership of the Class A ordinary shares held directly by the Sponsor. Read SEC document |
| April 30, 2020 Filed May 1, 2020 22:44 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 14,500 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-20-011753 · doc4.xml · derivative · entry 1 ALTMAN MICHAEL SETH · CIK 0001746738 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2030-04-29 F1 · derivative.exercise_date: This option vests and becomes exercisable in 36 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following April 30, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.